(FILE 'HOME' ENTERED AT 15:53:32 ON 20 NOV 2003)

FILE 'REGISTRY' ENTERED AT 15:53:45 ON 20 NOV 2003

L1 5 S GMQGPAGSGWEEGSGSPPGVTPLFSP/SQSP
L2 5 S GMQGPAGSGWEEGSGSPPGVTPLFSP/SQSP
L3 1 S L2 AND SQL<=30
L4 1 S L2 AND SQL<=35
L5 2 S L2 AND SQL<=40
L6 2 S L2 AND SQL<=50

FILE 'CAPLUS' ENTERED AT 15:56:49 ON 20 NOV 2003

L7 6 S L2
L8 4 S L3
L9 4 S L5

FILE 'REGISTRY' ENTERED AT 15:58:04 ON 20 NOV 2003

L10 4 S L2 AND SQL<=60
L11 4 S L2 AND SQL<=100

FILE 'BIOSIS, SCISEARCH, MEDLINE' ENTERED AT 15:58:32 ON 20 NOV 2003

L12 7 S ACTEYLCHOLINESTERASE
L13 0 S L12 AND HEMATOPOIETIC STEM CELL GROWTH
L14 47811 S ACETYLCHOLINESTERASE
L15 0 S L14 AND HEMATOPOIETIC STEM CELL GROWTH
L16 65 S HEMATOPOIETIC STEM CELL GROWTH
L17 0 S L16 AND ACH
L18 2 S L16 AND ENDOTHELIAL

(FILE 'HOME' ENTERED AT 18:40:05 ON 19 NOV 2003)

FILE 'REGISTRY' ENTERED AT 18:40:18 ON 19 NOV 2003

L1 1 S GMQGPAGSGWEEGSGSPPGVTPLFSP/SQEP

L2 1 S GMQGPAGSGWEEGSGSPPGVTPLFSP/SQEP

FILE 'CAPLUS' ENTERED AT 18:41:26 ON 19 NOV 2003

L3 4 S L1

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:449881 CAPLUS
DN 137:32069
TI Single-chain variable fragment antibodies specific for the synaptic variant of acetylcholinesterase (AChE-S) for diagnosis of progressive neuromuscular disorders
IN Soreq, Hermona; Flores, Cesar Flores; Nissim, Ahuva
PA Yissum Research Development Company of the Hebrew University of Jerusalem, Israel
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046422	A1	20020613	WO 2001-IL464	20010522
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001062611	A5	20020618	AU 2001-62611	20010522
PRAI	IL 2000-140071	A	20001204		
	WO 2001-IL464	W	20010522		

AB The invention relates to a nucleic acid sequence coding for single-chain variable fragment antibody that has specific affinity for synaptic variant of acetylcholinesterase (AChE-S). This single-chain variable fragment antibody consists essentially of a polypeptide comprising the binding portion of the heavy chain variable region of an antibody. The invention further relates to expression vehicle comprising said nucleic acid sequence coding for the anti AChE-S single-chain variable fragment antibody. Moreover, the invention relates to methods for the diagnosis of a progressive neuromuscular disorder in a mammal, preferably in humans and particularly myasthenia gravis, by using the single-chain variable fragment antibody of the invention.
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:236512 CAPLUS
DN 134:321192
TI ARP, a peptide derived from the stress-associated acetylcholinesterase variant, has hematopoietic growth promoting activities
AU Grisaru, Dan; Deutsch, Varda; Shapira, Michael; Pick, Marjorie; Sternfeld, Meira; Melamed-Book, Naomi; Kaufer, Daniela; Galyam, Nilly; Gait, Michael J.; Owen, David; Lessing, Joseph B.; Eldor, Amiram; Soreq, Hermona
CS Department of Biological Chemistry, Institute of Life Sciences, Hebrew University of Jerusalem, Israel
SO Molecular Medicine (Baltimore, MD, United States) (2001), 7(2), 93-105
CODEN: MOMEF3; ISSN: 1076-1551
PB Johns Hopkins University Press
DT Journal
LA English
AB Psychol. stress induces rapid and long-lasting changes in blood cell compn., implying the existence of stress-induced factors that modulate hematopoiesis. Here the authors report the involvement of the stress-assocd. "readthrough" acetylcholinesterase (A ChE-R) variant, and

its 26 amino acid C-terminal domain (ARP) in hematopoietic stress responses. The authors studied the effects of stress, cortisol, antisense oligonucleotides to A ChE, and synthetic ARP on peripheral blood cell compn. and clonogenic progenitor status in mice under normal and stress conditions, and on purified CD34+ cells of human origin. The authors employed in situ hybridization and immuno-cytochem. staining to monitor gene expression, and 5-bromo-2-deoxyuridine (BrdU), primary liq. cultures, and clonogenic progenitor assays to correlate A ChE-R and ARP with proliferation and differentiation of hematopoietic progenitors. The authors identified two putative glucocorticoid response elements in the human A CHE gene encoding A ChE. In human CD34+ hematopoietic progenitor cells, cortisol elevated A ChE-R mRNA levels and promoted hematopoietic expansion. In mice, a small peptide crossreacting with anti-ARP antiserum appeared in serum following forced swim stress. Ex vivo, ARP was more effective than cortisol and equally as effective as stem cell factor in promoting expansion and differentiation of early hematopoietic progenitor cells into myeloid and megakaryocyte lineages. The authors' findings attribute a role to A ChE-R and ARP in hematopoietic homeostasis following stress, and suggest the use of ARP in clin. settings where ex vivo expansion of progenitor cells is required.

RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:861777 CAPLUS
DN 134:25383
TI Acetylcholinesterase-derived peptides with cell growth/cell differentiation activity and uses in promotion of stem cell survival and myeloid and megakaryocytic differentiation
IN Soreq, Hermona; Eldor, Amiram; Deutch, Varda; Grisaru, Dan
PA Yissum Research Development Company of the Hebrew University of Jerusalem, Israel
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000073427	A2	20001207	WO 2000-IL311	20000531
	WO 2000073427	A3	20010222		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003036632	A1	20030220	US 2001-998042	20011130
PRAI	IL 1999-130224	A	19990531		
	IL 1999-131707	A	19990902		
	WO 2000-IL311	A2	20000531		

AB The invention relates to a cell growth and/or differentiation regulatory peptide comprising a sequence of about 9 to about 150 amino acids derived from acetylcholinesterase amino acid sequence, preferably from the C-terminal region of acetylcholinesterase. Preferred peptides comprise the 16 C-terminal amino acids of acetylcholinesterase readthrough variant (GMQGPAGSGWEEGSGSPPGVTPLFSP, designated ARP) and the 40 C-terminal residues of acetylcholinesterase S variant (DTLDEAERQWKAEFHRWSSYMVHWKNQFDH YSKQDRCSDL, designated ASP). The invention also relates to pharmaceutical

compns. comprising the peptides, particularly for use in promoting survival of stem cells, promoting differentiation of stem cells, promoting growth of stem cells and/or promoting the growth-enhancing effect of a growth factor on stem cells, alone, or in combination with other growth factors. Of particular interest is the use of the peptides in the treatment of thrombocytopenia, post-irradn. conditions, post-chemotherapy conditions, or conditions following massive blood loss and promotion of neural progenitors in use for cell therapies aimed at restoring neural functions in diseased individuals. Further, the invention relates to antibodies against the peptides, inter alia for diagnostic use, for example, the diagnosis of stress-induced male infertility.

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:861715 CAPLUS
DN 134:16510
TI Diagnosis of central nervous system pathology with antibodies to acetylcholinesterase C-terminal peptides
IN Soreq, Hermona; Kaufer, Daniela; Friedman, Alon; Seidman, Shlomo
PA Yissum Research Development Company of the Hebrew University of Jerusalem, Israel
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000073343	A2	20001207	WO 2000-IL312	20000531
	WO 2000073343	A3	20010118		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1187853	A2	20020320	EP 2000-931517	20000531
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	IL 1999-130225	A	19990531		
	WO 2000-IL312	W	20000531		

AB The authors disclose antibodies recognizing C-terminal peptides of the read-through variant of acetylcholinesterase. The read-through variant was found to be elevated under conditions of psychol., chem. or phys. insult to the central nervous system (CNS). These antibodies may be used in diagnosing CNS stress, disruption of the blood-brain barrier, or Alzheimer's disease.